Background Histone deacetylases (HDAC) contribute to oncogenic program, pointing to
their inhibitors as a potential strategy against cancers. We, thus, studied the mechanism of …

Histone deacetylase inhibitors (HDACi) are promising therapeutic agents which are
currently used in combination with chemotherapeutic agents in clinical trials for cancer …

Chemotherapy paclitaxel yields significant reductions in tumor burden in the majority of
advanced non-small cell lung cancer (NSCLC) patients. However, acquired resistance limits …

Objective: The novel compound GCJ-490A has been discovered as a pan-histone
deacetylase (HDAC) inhibitor that exerts potent inhibitory activity against HDAC1, HDAC3 …

Histone deacetylases (HDACs) are promising targets for cancer therapy, and first-generation
HDAC inhibitors are currently in clinical trials for the treatment of cancer patients. HDAC6 …

HDAC3 is one of the main targets of histone deacetylase (HDAC) inhibitors in clinical
development as cancer therapies, yet the in vivo role of HDAC3 in solid tumors is unknown …

Background Lung cancer is the leading cause of cancer mortality worldwide, yet the
therapeutic strategy for advanced non-small cell lung cancer (NSCLC) is limitedly effective …

Nonsmall cell lung cancer (NSCLC) is a predominant subtype of lung cancer and accounts
for over 80% of all lung cancer cases. The resistance to pemetrexed (PEM) is frequently …

Background MicroRNAs (miRNAs) function as tumor promoting or tumor suppressing factors
in many cancers. MiR‐520b contributes to progression in head‐neck and liver cancers …

Background/Aim: Histone deacetylase 6 (HDAC6) is considered as one of the most
promising targets in drug development for cancer therapy. Drug resistance is a major cause …